Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Champions Oncology, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 25 | 34 | +9 |
| Shares | 5.72M | 5.92M | +198.5K (+3.5%) |
| Value | $49.0M | $51.4M | +$2.35M (+4.8%) |
New holders (10)
Institutions that held Champions Oncology, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EAM Investors, LLC | 79,987 | $694.3K | 0.12% |
| Hillsdale Investment Management Inc. | 26,100 | $226.5K | 0.01% |
| Goldman Sachs Group Inc | 23,129 | $200.8K | 0.00% |
| Jane Street Group, LLC | 23,020 | $199.8K | 0.00% |
| O'Shaughnessy Asset Management, LLC | 18,920 | $164.2K | 0.00% |
| Omers Administration Corp | 10,700 | $92.9K | 0.00% |
| Royal Bank of Canada | 7,626 | $66.0K | 0.00% |
| Citigroup Inc | 4,915 | $42.7K | 0.00% |
| UBS Group AG | 529 | $4.59K | 0.00% |
| Garde Capital, Inc. | 1 | $9 | 0.00% |
Sold out (1)
Institutions that held Champions Oncology, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Virtu Financial LLC | 11,051 | $95.0K |